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Abstract
Background: TWIST1 and CD105, which contribute to tumor malignancy, are overexpressed in cancers.
Accordingly, TWIST1 enhances epithelial-to-mesenchymal transition (EMT) and promotes the formation of cancer
stem cells (CSCs). Also, CD105 is a neoangiogenesis marker in endothelial cells, which is introduced as a CSC marker
in tumoral epithelial cells in several types of cancers. The present study was aimed to investigate expressions of
TWIST1 and CD105 in colorectal cancer (CRC) patients.
Methods: Expressions of TWIST1 and CD105 in 250 CRC tissue samples were evaluated using
immunohistochemistry on tissue microarrays (TMAs). In this regard, TWIST1 expression was investigated in the
subcellular locations (cytoplasm and nucleus), while CD105 was mapped in endothelial cells and cytoplasmic tumor
cells of CRC tissues. The association between the expression of these markers and clinicopathological parameters, as
well as survival outcomes were analyzed.
Results: Results indicate a statistically significant association between higher nuclear expression levels of TWIST1
and distant metastases in CRC (P = 0.040) patients. In addition, it was shown that the increased nuclear expression
of TWIST1 had a poor prognostic value for disease-specific survival (DSS) and progression-free survival (PFS) (P =
0.042, P = 0.043, respectively) in patients with CRC. Moreover, analysis of CD105 expression level has revealed that
there is a statistically significant association between the increased expression of CD105 in tumoral epithelial cells
and more advanced TNM stage (P = 0.050).
Conclusions: Our results demonstrate that nuclear TWIST1 and cytoplasmic CD105 expressions in tumor cells had
associations with more aggressive tumor behavior and more advanced diseases in CRC cases.
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Background
Colorectal cancer (CRC), as a major health concern in
both genders, is known as the second leading cause of
cancer death worldwide. CRC ranks as the third inci-
dence rate with over 1.8 million new cases reported by
the World Health Organization in 2018 [1]. Despite the
advances in screening tests and treatment of CRC, the 5-
year survival rate was estimated as 65% in high-income
countries; however, it has remained less than 50% in
low-income developing countries [2]. Nowadays, there is
a need for discovering universal biomarkers in CRC to
be used in clinical practice; therefore, performing studies
on CRC biomarkers is increasing. The findings of such
studies may affect the diagnosis and prognosis of pa-
tients with CRC, which may help in increasing their life-
spans [2, 3].
Changes in genetic and epigenetic due to some factors
can lead to epithelial-to-mesenchymal transition (EMT)
in epithelial neoplastic cells [4], which causes migration
of these cells from primary tissue to stromal components
[5]. Epithelial cells lose intercellular junctions, reorganize
cell cytoskeleton, and gain migratory properties during
the EMT process, which all increase mobility of cells [6].
Several studies have shown that EMT is importantly as-
sociated with a poor prognosis in the cancerous patients
[7]. In this regard, several markers to induce EMT have
been described such as TWIST proteins, matrix metallo-
peptidases (MMPs), transforming growth factor beta
(TGF-β), and TGF-β receptor [6, 8].
Most of the tumor cells use EMT-associated transcrip-
tion factors (EMT-TFs), which were identified as key
participants in the EMT program [9]. TWIST1, as one
of the EMT-TFs, is involved in EMT through the down-
regulation of E-cadherin and regulates apoptosis by
interacting with p53 protein [10, 11]. Accordingly, this
protein plays multiple roles in cancers and mediates cell
migration and differentiation. In addition, some reports
indicated that TWIST1 is associated with angiogenesis
and stemness in various cancers [11–13]. As described
earlier in a review report, overexpression and role of
TWIST1 were observed in various cancers such as pros-
tatic cancer, gastric cancer, breast cancer, and CRC [11].
Findings indicated that CRC patients with positive
TWIST1 expression in tumor cells have low survival
rates [14]. In addition, some evidence showed that
TWIST1 may regulate endothelial markers, so that over-
expression of TWIST1 in oral squamous carcinoma cells
is associated with the expression and activation of
CD105 marker [15, 16].
TGF-β receptor is an important key inducer of EMT-
TFs, which changes expression levels of EMT markers in
CRC [17, 18]. CD105 (endoglin), as a neoangiogenesis-
related protein, is known as a component of TGF-β re-
ceptor and a regulator for TGF-β signaling [19]. Studies
performed on cancer have reported that CD105 may in-
duce EMT program through EMT-TFs and play a func-
tional role in maintaining cancer stem cells (CSCs) [20,
21]. Moreover, CD105 is considered as an appropriate
marker for angiogenesis that regulates proliferating
endothelial cells and blood vessels’ development [22].
CD105 contributes to all malignancies, which can be up-
regulated by hypoxia and TGF-βs; therefore, it can help
in promoting tumor proliferation and metastasis in sev-
eral types of cancer [22–24]. Studies have shown that
overexpression of endothelial CD105 is associated with
the advanced cancer, so CD105 can be considered as a
prognosis marker and as a targeted therapy [25–27].
Also, the increased expression of CD105 was observed
in aggressive and metastatic CRC patients [14, 28].
Although TWIST1 and CD105 expressions have been
shown as poor prognosis markers in CRC, very little in-
formation has been reported on the expression levels of
these markers based on subcellular location in CRC
samples. Thus, in this study, we investigated the associ-
ation between cytoplasmic and nuclear TWIST1 expres-
sion, as well as the association of CD105 expression in
endothelial cells and cytoplasmic tumor cells with clini-
copathological parameters and survival outcomes in pa-
tients with CRC through immunohistochemistry (IHC)
staining using tissue microarray (TMA) method.
Methods
Patients and tumor samples collection
In the present study, formalin-fixed paraffin-
embedded (FFPE) blocks of 250 CRC patients were
collected from the labs of three referral hospitals
(Hashemi Nejad, Firoozgar, and Rasoole Akram) in
Tehran, Iran, from 2012 to 2018. Patients who had
undergone surgical treatment by receiving no relevant
chemotherapy or radiotherapy were included in this
study. The hematoxylin and eosin (H & E) stained
slides and the information of clinicopathological pa-
rameters including age, gender, tumor size, tumor dif-
ferentiation, TNM stage, vascular invasion (VI), lymph
node invasion (LNI), neural invasion (NI), distant me-
tastasis, and tumor recurrence were also collected.
Moreover, 50 adjacent normal tissues were included
in this study. The enrolled patients were followed up
until March 2020 and patient outcome information
including disease-specific survival (DSS), which was
defined as the time from tumor resection to death
time due to CRC and progression-free survival (PFS),
which is the time from tumor resection until last
follow-up (patients with no evidence of disease, recur-
rence or progression), were collected. In addition,
pathological stage was described in terms of cancer
staging manual of the American Joint Committee on
Cancer (AJCC) in 2018 [29].
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Tissue microarray (TMA) construction
TMA blocks were constructed as described earlier [30].
Three representative tumor region cores were micro-
scopically selected on H & E slides. The representative
areas for TMA blocks included both superficial epithelial
foci and deep foci (where the tumor invades mesenchy-
mal tissue). Correspondingly, three cores were randomly
extracted from representative areas using a 0.6-mm
punch of FFPE tissue blocks from CRC patients. The
cores were placed using a precision arraying instrument
(Tissue Arrayer Minicore; ALPHELYS, Plaisir, France)
into recipient TMA blocks. Five-micrometer-thick were
obtained by cutting array blocks and putting them on
adhesive slides. TMA blocks were built in three copies
for each specimen of different areas and the mean scor-
ing of the three cores was then calculated as the final
score. It was shown that three copies in TMA-IHC
method could increase accuracy up to 99%, while the sin-
gle core has 90% accuracy [31].
Immunohistochemistry (IHC) staining
IHC staining was performed for TWIST1 and CD105
on those sections that were cut from the TMA
blocks. TMA sections were deparaffinized (for 30 min
at 60 °C), rehydrated with xylenes, and then graded by
ethanol. Afterward, they were incubated in 3% H2O2
for 20 min at room temperature until endogenous
peroxidase blockage on sections. Thereafter, antigen
tissue was exposed by antigen retrieval processing
that includes heating tissue sections in sodium citrate
buffer (pH = 6.0) for TWIST1 and Tris-EDTA (pH =
9.0) for CD105 by autoclave for 10 min. Subsequently,
the primary antibodies were separately incubated
overnight at 4 °C with rabbit monoclonal antibody
against TWIST1 and CD105 (TWIST1: ab49254; 1:80
dilution and CD105: ab169545; 1:400 dilution, Abcam,
Cambridge, MA, USA). After washing for 3 times in
Tris-buffered saline, the secondary antibody was incu-
bated for tissue slides with anti-rabbit/anti-mouse En-
vision (Dako, Glostrup, Denmark) for 30 min. In
order to visualize the antigen, 3, 3′-diaminobenzidine
substrate (DAB) (Dako, Glostrup, Denmark) was ap-
plied as chromogen for 10 min at room temperature.
The slides were then treated with hematoxylin (Dako,
Glostrup, Denmark), as a counterstain, for 3 min. Fi-
nally, to prepare the scoring, the slides were dehy-
drated in alcohol and then cleared in xylenes. Positive
and negative controls were used in each run of the
experiment. Manufacturer’s recommendations for
positive control tissue were human normal testis and
human normal kidney tissues for TWIST1 and
CD105 staining, respectively. For negative controls,
primary antibodies were replaced by Tris-buffered sa-
line (TBS).
Assessment of immunohistochemical staining
Immunohistochemical markers were also assessed by
two pathologists (Z.HS and Z.M) who were blinded to
pathological parameters and the patients outcomes.
Initially, 10 X magnification was used for TMA slides to
obtain a general impression of distribution cells, and
positive cells were then investigated by applying a semi-
quantitative scoring system at higher magnifications (40
X). A consensus was reached by two pathologists for
scoring samples. Also, staining was determined by the
immunostaining intensity (0: absent, 1: weak, 2: moder-
ate or 3: strong) and the percentage of positive tumor
cells was also categorized as follows: < 25, 25 to 50%, 51
to 75%, and > 75%. Finally, H-score was assigned based
on multiplying the intensity score by the percentage of
the stained cells, which was given to each core ranging
from 0 to 300 [32]. The average of the three cores was
calculated as the final score. In this study, mean H-score
was chosen to categories’ samples as high or low
expression.
Statistical analysis
Statistical analysis of data was performed by SPSS v.22.0
software (IBM Corp., Armonk, NY, USA). Kruskal–Wal-
lis and Mann–Whitney U tests were then performed to
compare groups. Chi-square and Spearman’s correlation
tests were also used to analyze the significance of associ-
ation and correlation between expression level of the
markers and clinicopathological parameters.
The survival analysis was performed using Kaplan–
Meier method, and Log-rank test was then applied to
compare the estimated curves between the groups (high
expression compared to low expression). Univariate and
multivariate analyses were performed by Cox propor-
tional hazard models. In order to determine which one
of the variables affected DSS or PFS, those variables that
significantly affected the survival in univariate analysis
were used in multivariable analyses. Quantitative data
were reported as mean (SD) and median (Q1, Q3). P-




In the current study, out of 250 CRC cases in total, 223
patients including 114 men (51.1%) and 109 women
(48.9%) were evaluated for TWIST1 expression. Patients’
ages ranged from 20 to 91 years old (mean age = 59,
SD = 14.6). Whereas, 208 CRC patients including 111
men (53.4%) and 97 women (46.6%) with the age range
of 25–88 years old (mean age = 59, SD = 13.6) were in-
vestigated for CD105 expression. The clinicopathological
features for our samples are shown in Table 1.
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Expression of TWIST1 and CD105 markers in CRC patients
The expression levels of TWIST1 and CD105 markers
were investigated using IHC on TMAs of CRC patients.
Scoring was done in terms of three methods, which in-
clude the following: intensity of staining, percentage of
positive cells, and H-score (Table 2). TWIST1 was
expressed at different sites (both nucleus and cytoplasm)
in the tumor cells, while CD105 was detected in endo-
thelial cells and cytoplasm of tumor cells of the obtained
CRC samples. Lower levels of expressions of TWIST1
and CD105 were observed in adjacent normal tissues
compared to the tumor samples. In human normal testis
sample, as a positive control for TWIST1, presented
cytoplasmic staining in seminiferous epithelial cells.
Moreover, human normal kidney tissue that was used as
a positive control for CD105 marker showed staining in
all endothelial cells, tubule capillaries, and glomerular
endothelial cells, but no staining was shown in tubule
cells (Figs. 1 and 2).
Association between cytoplasmic and nuclear expression
of TWIST1 with clinicopathological parameters
TWIST1 staining was observed in cytoplasm and nu-
cleus of tumor cells in all the obtained CRC samples.
Chi-square test analysis showed a statistically significant
association between the increased expression of nuclear
TWIST1 expression and distant metastasis (P = 0.040).
Whereas, no statistically significant association was ob-
served between cytoplasmic TWIST1 expression levels
and clinicopathological parameters in the cases studied
(Table 3).
Association between tumoral cytoplasmic and endothelial
expressions of CD105 with clinicopathological parameters
Endothelial CD105 expression was observed in all
the samples of CRC, while cytoplasmic expression of
CD105 in tumor cells was detected in 164 (78.8%)
CRC samples. Moreover, the results of Spearman’s
correlation test demonstrated a statistically signifi-
cant positive correlation between CD105 expression
in endothelial and tumor cells of CRC samples (P =
0.007, rs: 0.18).
The results of Chi-square test indicated a statistically
significant association between cytoplasmic CD105 ex-
pression levels and the advanced TNM stage (P = 0.050).
Also, Kruskal–Wallis test to compare the mean expres-
sion levels of CD105 in different groups, revealed a sta-
tistically significant difference between cytoplasmic
CD105 expression and various TNM stages (I–IV) (P =
0.050). Furthermore, Mann–Whitney U test demon-
strated a significant difference in terms of the mean level
of cytoplasmic CD105 expression between TNM stages
II and IV (P = 0.028) (Fig. 3). The mean expression levels
of cytoplasmic CD105 expression in tumor cells for
stages II and IV were 22 and 48, respectively. No signifi-
cant association was observed between cytoplasmic
CD105 expression levels and the other clinicopathologi-
cal parameters in CRC cases (Table 4).
Table 1 Patients and tumor pathological parameters of the
studied population
Patients and tumor characteristics TWIST1 marker CD105 marker
Number of CRC samples 223 208
Mean age, years (Range) 59 (20–91) 59 (25–88)
≤Mean age 110 (49.3) 105 (50.5)
> Mean age 113 (50.7) 103 (49.5)
Gender
Male 114 (51.1) 111 (53.4)
Female 109 (48.9) 97 (46.6)
(Male/Female) 1.04 1.14
Mean tumor size (cm) 5 5
≤Mean 156 (70.0) 145 (69.7)
> Mean 67 (30.0) 63 (30.3)
Tumor differentiation
Well 103 (46.2) 89 (42.8)
Moderate 104 (46.6) 107 (51.4)
Poor 16 (7.2) 12 (5.8)
TNM stage
I 40 (17.9) 29 (13.9)
II 98 (43.9) 92 (44.2)
III 79 (35.4) 80 (38.5)
IV 6 (2.7) 7 (3.4)
Vascular invasion (VI)
Present 36 (16.1) 37 (17.8)
Absent 187 (83.9) 171 (82.2)
Lymph node invasion (LNI)
Involved 82 (36.8) 83 (39.9)
None 141 (63.2) 125 (60.1)
Neural invasion (NI)
Involved 47 (21.1) 57 (27.4)
None 176 (78.9) 151 (72.6)
Distant metastasis
Present 37 (16.6) 30 (14.4)
Absent 100 (44.8) 90 (43.3)
Not identified 86 (38.6) 88 (42.3)
Tumor recurrence
Yes 42 (18.8) 36 (17.3)
No 95 (42.6) 85 (40.9)
Not identified 86 (38.6) 87 (41.8)
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Table 2 TWIST1 and CD105 expression (Intensity of staining, percentage of positive tumor cells, and H-score) in colorectal cancer
(CRC) samples
Scoring system Cytoplasmic TWIST1 N (%) Nuclear TWIST1 N (%) Cytoplasmic CD105 N (%) Endothelial CD105 N (%)
Intensity of staining
No staining (0) 0 (0.0) 0 (0.0) 44 (21.2) 0 (0.0)
Weak (+ 1) 111 (49.8) 69 (30.9) 161 (77.4) 0 (0.0)
Moderate (+ 2) 106 (47.5) 123 (55.2) 3 (1.4) 25 (12.0)
Strong (+ 3) 6 (2.7) 31 (13.9) 0 (0.0) 183 (88.0)
Percentage of positive tumor cells
< 25% 0 (0.0) 0 (0.0) 121 (58.2) 0 (0.0)
25–50% 0 (0.0) 1 (0.4) 60 (28.8) 0 (0.0)
51–75% 3 (1.3) 20 (9.0) 13 (6.3) 6 (2.9)
> 75% 220 (98.7) 202 (90.6) 14 (6.7) 202 (97.1)
H-score cut off 149 172 26 284
Low 113 (50.7) 87 (39.0) 121 (58.2) 34 (16.3)
High 110 (49.3) 136 (61.0) 87 (41.8) 174 (83.7)
Total 223 223 208 208
H-score indicates histological score
Fig. 1 Immunohistochimecal staining of TWIST1 in colorectal cancer (CRC) tissues, adjacent normal tissues, and normal testis controls. Nuclear
TWIST1 expression in tumor cells: low expression a-a1 and high expression b-b1. Cytoplasmic TWIST1 expression in tumor cells: low expression c-
c1 and high expression d-d1. Adjacent normal tissues e-e1. Normal testis tissues as controls: positive f and negative g
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Prognostic value of TWIST1 expression for clinical
outcome
Of 223 patients included in this study, follow-up data
were available only for 138 CRC samples. Also, the
follow-up period was between 1 and 105months with
mean and median of follow-up time as 38 (SD = 23.3)
and 38 (Q1 = 20, Q3 = 53) months, respectively. Ninety-
three (67.9%) cases had no history of recurrence and dis-
tant metastasis, while 44 (32.1%) of them reported a his-
tory of these events’ occurrence. Distant metastasis and
recurrence were observed in 37 (27.0%) and 42 (30.7%)
patients, whereas 100 (73.0%) and 95 (69.3%) patients
were negative, respectively. During the follow-up period,
cancer-related death was seen in 43 (31.1%) patients.
Survival outcomes based on expression of TWIST1
The results of Kaplan-Meier analysis demonstrated a sta-
tistically significant differences in DSS between the pa-
tients with high and low expression levels of nuclear
TWIST1 (Log Rank test, P = 0.042) (Fig. 4a). The mean
DSS time was 60 (SD = 4.5) months for patients with
high expression levels of nuclear TWIST1, and 84 (SD =
5.7) months for patients with low expression levels of
that. The 5-year DSS survival rates of the patients who
expressed high and low nuclear expressions of TWIST1
were 60 and 74%, respectively (P = 0.030). Moreover, the
results of survival analysis indicated that patients with
high expression levels of nuclear TWIST1 had signifi-
cantly lower PFS (Log Rank test, P = 0.043) (Fig. 4b). In
this regard, mean PFS time for patients with high nu-
clear TWIST1 expression was calculated as 58 (SD = 4.4)
months, while it was 81 (SD = 5.9) months for patients
with low nuclear TWIST1 expression. The 5-year PFS
survival rates of the patients who expressed high and
low nuclear expressions of TWIST1 were 55 and 72%,
respectively (P = 0.026). Kaplan-Meier analysis showed
no significant difference in survival analyses (DSS and
PFS) between the patients with high and low cytoplasmic
expressions’ levels of TWIST1 (Log Rank test, DSS and
PFS analysis for cytoplasmic TWIS1 expression, P =
0.320 and P = 0.320, respectively) (Fig. 4c and d).
Also, univariate and multivariate analyses were per-
formed to investigate whether TWIST1 expression is an
independent prognostic factor of DSS or PFS, as well as
assessing the clinical significance of various parameters
that might affect survival outcomes among patients with
Fig. 2 Immunohistochimecal staining of CD105 in colorectal cancer tissues (CRC), adjacent normal tissues, and normal testis controls. Cytoplasmic
CD105 expression in tumor cells: low expression a-a1 and high expression b-b1. CD105 expression in endothelial cells: low expression c-c1 and
high expression d-d1. Adjacent normal tissues e-e1. Normal kidney tissues as controls: positive f and negative g
Fattahi et al. Diagnostic Pathology           (2021) 16:26 Page 6 of 15
CRC. Univariate analysis has demonstrated that several
parameters including nuclear TWIST1 expression (P =
0.048), tumor size (P = 0.040), tumor differentiation
(P < 0.001), vascular invasion (P = 0.030), neural invasion
(P < 0.001), lymph node invasion (P = 0.033), distant me-
tastasis (P < 0.001), and tumor recurrence (P < 0.001)
Table 3 The association between cytoplasmic and nuclear TWIST1 expressions and clinicopathological parameters of colorectal














Low (≤ 149) High (> 149) Low (≤ 172) High (> 172)
Number of CRC samples 223 113 (50.7) 110 (49.3) 87 (39.0) 136 (61.0)
Mean age, years (Range) 59 (20–91) 0.159 0.262
≤Mean age 110 (49.3) 61 (54.0) 49 (44.5) 47 (54.0) 63 (46.3)
> Mean age 113 (50.7) 52 (46.0) 61 (55.5) 40 (46.0) 73 (53.7)
Gender 0.095 0.129
Male 114 (51.1) 64 (56.6) 50 (45.5) 50 (57.5) 64 (47.1)
Female 109 (48.9) 49 (43.4) 60 (54.5) 37 (42.5) 72 (52.9)
(Male/Female) 1.04 1.30 0.83 1.35 0.88
Mean tumor size (cm) 5 0.389 0.522
≤Mean 156 (70.0) 82 (72.6) 74 (67.3) 63 (72.4) 93 (68.4)
> Mean 67 (30.0) 31 (27.4) 36 (32.7) 24 (27.6) 43 (31.6)
Tumor differentiation 0.549 0.405
Well 103 (46.2) 53 (46.9) 50 (45.5) 45 (51.7) 58 (42.6)
Moderate 104 (46.6) 50 (44.2) 54 (49.1) 36 (41.4) 68 (50.0)
Poor 16 (7.2) 10 (8.8) 6 (5.5) 6 (6.9) 10 (7.4)
TNM stage 0.932 0.831
I 40 (17.9) 19 (16.8) 21 (19.1) 16 (18.4) 24 (17.6)
II 98 (43.9) 52 (46.0) 46 (41.8) 40 (46.0) 58 (42.6)
III 79 (35.4) 39 (34.5) 40 (36.4) 28 (32.2) 51 (37.5)
IV 6 (2.7) 3 (2.7) 3 (2.7) 3 (3.4) 3 (2.2)
Vascular invasion (VI) 0.783 0.445
Present 36 (16.1) 19 (16.8) 17 (15.5) 12 (13.8) 24 (17.6)
Absent 187 (83.9) 94 (83.2) 93 (84.5) 75 (86.2) 112 (82.4)
Lymph node invasion (LNI) 0.878 0.571
Involved 82 (36.8) 41 (36.3) 41 (37.3) 30 (34.5) 52 (38.2)
None 141 (63.2) 72 (63.7) 69 (62.7) 57 (65.5) 84 (61.8)
Neural invasion (NI) 0.697 0.653
Involved 47 (21.1) 25 (22.1) 22 (20.0) 17 (19.5) 30 (22.1)
None 176 (78.9) 88 (77.9) 88 (80.0) 70 (80.5) 106 (77.9)
Distant metastasis 0.234 0.045
Present 37 (16.6) 15 (13.3) 22 (20.0) 8 (9.2) 29 (21.3)
Absent 100 (44.8) 52 (46.0) 48 (43.6) 40 (46.0) 60 (44.1)
Not identified 86 (38.6) 46 (40.7) 40 (36.4) 39 (44.8) 47 (34.6)
Tumor recurrence 0.568 0.149
Yes 42 (18.8) 19 (16.8) 23 (20.9) 11 (12.7) 31 (22.8)
No 95 (42.6) 48 (42.5) 47 (42.7) 37 (42.5) 58 (42.6)
Not identified 86 (38.6) 46 (40.7) 40 (36.4) 39 (44.8) 47 (34.6)
H-score indicates histological score
Values in bold are statistically significant
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may affect DSS (Table 5). Accordingly, the results of
univariate analysis for PFS including nuclear TWIST1
expression (P = 0.049), tumor differentiation (P < 0.001),
neural invasion (P < 0.001), lymph node invasion (P =
0.038), distant metastasis (P < 0.001), and tumor recur-
rence (P < 0.001), are summarized in Table 6. While
multivariate analysis indicated that only tumor differen-
tiation is an independent prognostic factor that affect
the DSS and PFS of patients with CRC (Cox regression,
DSS and PFS analysis, P = 0.003 and P < 0.001,
respectively).
Prognostic value of CD105 expression for clinical
outcome
Follow-up data of 121 CRC samples were available for
CD105 expression analysis. The range of follow up time
was from 1 to 105 months with the mean follow-up time
of 37 (SD = 25.1) and median of 35 months (Q1 = 20,
Q3 = 50). Eighty-three (68.8%) patients had no history of
recurrence and distant metastasis, while in 38 (31.2%)
patients reported history of these events’ occurrence.
Distant metastasis and recurrence were observed in 30
(24.7%) and 36 (29.8%) patients, whereas 91 (75.3%) and
85 (70.2%) patients were negative, respectively. During
the follow-up period, cancer-related death has occurred
in 37 (30.5%) patients.
Survival outcomes based on expression of CD105
The results of Kaplan-Meier curves showed that there
were no significant differences in terms of the survival
analysis of DSS or PFS between the patients with high
and low expression’ levels of CD105 (Log Rank test, DSS
and PFS analysis for cytoplasmic CD105 expression in
tumor cells, P = 0.928 and P = 0.990, respectively) (Fig. 5
A and 5B) and (Log Rank test, DSS and PFS analysis for
endothelial CD105 expression, P = 0.641 and P = 0.405,
respectively) (Fig. 5c and d).
In addition, the results of univariate and multivariate
analyses showed that the clinicopathological parameters
cannot be considered as significant factors for the DSS
or PFS of patients with CRC.
Discussion
EMT is an important biological concept of cell plasticity
that contributes to the progression of cancer. EMT
process is associated with some changes in motility and
invasion ability of cells. Moreover, EMT is initiated with
some alterations in signaling pathway’s regulation and
EMT-TFs expression such as TGF-β signaling and TWIS
T1 [6]. Some evidence indicated that the alteration in the
EMT-TFs activation is due to changes in signaling cas-
cades, which may affect clinical outcomes related to can-
cer. Therefore, the signaling pathways leading to these
changes can be used as therapeutic targets [33, 34].
TWIST1 is known as one of EMT-TFs that plays some
critical roles in the tumor growth’s initiation, invasion,
and metastasis [9]. In addition, it participates in carcin-
oma progression that is associated with worse survival in
various cancers [35] such as ovarian [36], bladder [37],
liver [38], and kidney cancers [39]. Recently, special at-
tention has been paid to TWIST1, because it contributes
in the generations of CSCs and vasculogenic mimicry
(VM) through inducing stemness properties and endo-
thelial markers [15, 40]. The induction of EMT, as well
as the phenotype of the CSC by TWIST1, enhances mi-
gration and invasion in CRC [40]. CSCs are known as
subpopulations of cancer cells that are responsible for
tumor progression, metastasis, angiogenesis, and resist-
ance to chemotherapeutic agents [41, 42].
In the present study, we investigated the TWIST1 ex-
pression in a large sample of CRC patients by consider-
ing scoring as well as separately analyzing the nuclear
and cytoplasmic TWIST1 expressions. Although most of
the previous results have demonstrated cytoplasmic
TWIST1 expression, very few studies reported nuclear
TWIST1 expression in CRC [43–45]. Nuclear and cyto-
plasmic TWIST1 expressions were observed in all CRC
samples of this study. Correspondingly, this result con-
firms earlier findings reported that most tumor cells use
EMT-TFs [9]. As expected, our results demonstrate that
CRC tissues had higher cytoplasmic and nuclear TWIS
T1 expression’s levels compared to adjacent normal tis-
sues, which is consistent with previous results reporting
cytoplasmic TWIST1 expression in CRC and normal tis-
sues [46]. Our investigation on the increased nuclear
TWIST1 expression levels showed a statistically
Fig. 3 Box plot of cytoplasmic CD105 expression levels for TNM
stage in colorectal cancer. Based on the standard definitions, each
box-plot shows the median (bold line) and interquartile lines (box).
The results of Mann–Whitney U test showed that there was a
statistically significant difference in terms of the mean expression
levels of CD105 between stage II and IV in tumor cells (P = 0.028)
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significant association with distant metastasis among
CRC patients, while no significant association was found
between the cytoplasmic expression of TWIST1 and
distant metastasis. Accordingly, this result is in line with
the claim that cytoplasm translocation to the nucleus of
TWIST1 is associated with late events in CRC [43]. The
Table 4 The association between cytoplasmic and endothelial CD105 expressions and clinicopathological parameters of colorectal














Low (≤ 26) High (> 26) Low (≤ 284) High (> 284)
Number of CRC samples 208 121 (58.2) 87 (41.8) 34 (16.3) 174 (83.7)
Mean age, years (Range) 59 (25–88) 0.796 0.358
≤Mean age 105 (50.5) 62 (51.2) 43 (49.4) 20 (58.9) 85 (48.9)
> Mean age 103 (49.5) 59 (48.8) 44 (50.6) 14 (41.1) 89 (51.1)
Gender 0.872 0.305
Male 111 (53.4) 64 (52.9) 47 (54.0) 15 (44.1) 96 (55.2)
Female 97 (46.6) 57 (47.1) 40 (46.0) 19 (55.9) 78 (44.8)
(Male/Female) 1.14 1.12 1.17 0.78 1.23
Mean tumor size (cm) 5 0.472 0.693
≤Mean 145 (69.7) 82 (67.8) 63 (72.4) 23 (67.7) 122 (70.1)
> Mean 63 (30.3) 39 (32.2) 24 (27.6) 11 (32.3) 52 (29.9)
Tumor differentiation 0.605 0.450
Well 89 (42.8) 55 (45.5) 34 (39.1) 12 (35.2) 77 (44.3)
Moderate 107 (51.4) 60 (49.6) 47 (54.0) 21 (61.7) 86 (49.4)
Poor 12 (5.8) 6 (5.0) 6 (6.9) 1 (3.1) 11 (6.3)
TNM stage 0.050 0.631
I 29 (13.9) 14 (11.6) 15 (17.2) 7 (20.5) 22 (12.6)
П 92 (44.2) 62 (51.2) 30 (34.5) 13 (38.2) 79 (45.4)
III 80 (38.5) 43 (35.5) 37 (42.5) 13 (38.2) 67 (38.5)
IV 7 (3.4) 2 (1.7) 5 (5.7) 1 (3.1) 6 (3.4)
Vascular invasion (VI) 0.587 0.711
Present 37 (17.8) 23 (19.0) 14 (16.1) 6 (17.6) 31 (17.8)
Absent 171 (82.2) 98 (81.0) 73 (83.9) 28 (82.4) 143 (82.2)
Lymph node invasion (LNI) 0.713 0.978
Involved 83 (39.9) 47 (38.8) 36 (41.4) 14 (41.1) 69 (39.7)
None 125 (60.1) 74 (61.2) 51 (58.6) 20 (58.9) 105 (60.3)
Neural invasion (NI) 0.371 0.241
Involved 57 (27.4) 36 (29.8) 21 (24.1) 12 (35.2) 45 (25.9)
None 151 (72.6) 85 (70.2) 66 (75.9) 22 (64.8) 129 (74.1)
Distant metastasis 0.662 0.438
Present 30 (14.5) 20 (16.5) 10 (11.5) 3 (8.9) 27 (15.5)
Absent 91 (43.7) 57 (47.1) 34 (39.1) 16 (47.0) 75 (43.1)
Not identified 87 (41.8) 44 (36.4) 43 (49.4) 15 (44.1) 72 (41.4)
Tumor recurrence 0.707 0.530
Yes 36 (17.3) 22 (18.1) 14 (16.1) 4 (11.8) 32 (18.4)
No 85 (40.9) 55 (45.5) 30 (34.5) 14 (41.2) 71 (40.8)
Not identified 87 (41.8) 44 (36.4) 43 (49.4) 16 (47.0) 71 (40.8)
H-score indicates histological score
Values in bold are statistically significant
Fattahi et al. Diagnostic Pathology           (2021) 16:26 Page 9 of 15
significance of TWIST1 expression in CRC is still con-
troversial, in a way that some studies have shown that
expression level of TWIST1 is positively correlated with
lymph node metastasis and stage among CRC cases [14,
46]. However, the other CRC studies have reported no
relationship among TWIST1 expression and metastasis
and stage [47, 48]. These differences can be explained, in
part, by considering the fact that TWIST1 acts as EMT-
TF in the nucleus [9, 49] and these studies have not dis-
tinguished subcellular location of TWIST1 expression or
they have only focused on cytoplasmic TWIST1 expres-
sion. To the best of our knowledge, TWIST1 contributes
to cancer progression by nucleosome remodeling that
alters the regulation of some other factors such as the
reduced E-cadherin and induced BMI1 proto-oncogene
leading to the increased motility of tumor cells and can-
cer stemness features, respectively [11, 49].
Although a few studies in the past reported nuclear
expression of TWIST1 in CRC tissues [43–45], we
showed for the first time in the current study a statisti-
cally significant association between nuclear expression
of TWIST1 and survival outcomes in CRC patients. Our
findings showed that CRC patients with a higher expres-
sion of nuclear TWIST1 had statistically significant
lower DSS and PFS rates compared to those with a
lower expression of nuclear TWIST1. Moreover, CRC
Fig. 4 Kaplan-Meier curves for disease-specific survival (DSS) and progression-free survival (PFS) according to the expression levels of TWIST1 in
colorectal cancer. (Nuclear and cytoplasmic TWIST1 expression in tumor cells was divided into two groups as follows: high and low expression
levels). a Log Rank test showed that patients with a high nuclear TWIST1 expression had shorter DSS and b PFS compared to patients with a low
nuclear TWIST1 expression (P = 0.042 and P = 0.043, respectively). c, d The Kaplan–Meier survival analysis showed that there were no significant
differences in terms of survival (DSS and PFS) between patients with high and low cytoplasmic TWIST1 expressions (Survival analysis: DSS (P =
0.320) and PFS (P = 0.320))
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patients who showed a higher level of TWIST1 had
shorter 5-year survival rate for DSS and PFS compared
to those with a low expression. Furthermore, we found
that tumor differentiation is an independent prognostic
factor for DSS and PFS in nuclear expression pattern,
while there was no association among TWIST1 expres-
sion and clinicopathological features and survival out-
comes in cytoplasmic expression. In this study, we
showed that TWIST1 protein expression is a prognostic
marker for DSS and PFS in CRC patients (as found in
univariate analysis). However, this association wasn’t in-
dependently significant in the multivariate analysis. As
there was a positive trend in this association, increasing
the number of the cases may have improved this value
in multivariate analysis. These results suggest that nu-
clear TWIST1 expression might be considered as a
predictor for the poor survival in CRC patients. More-
over, our result highlights the importance of nuclear ex-
pression compared to the cytoplasmic expression of
TWIST1, because the nucleus is known as a site for the
initiation of cell reprogramming by EMT-TFs. It was
found that TWIST1 mostly depends on the activation of
the TGF-β receptor for chromatin binding that induce
migration and invasion [50].
In the current study, we have also investigated CD105
expression, as an accessory for TGF-β receptor, in endo-
thelial and tumor cells of CRC tissues that plays a role
in the TGF-β signaling pathway. TGF-β signaling can ac-
tivate EMT leading to the induced CSC formation in the
epithelial cells [51, 52]. Although the role of TGF-β re-
ceptor was indicated in EMT, few reports have demon-
strated that CD105 is involved in EMT [20, 21].
Table 6 Univariate and multivariate Cox regression analyses of potential prognostic factor for progression- free survival (PFS) in
patients with colorectal cancer
Covariate Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
Nuclear TWIST1 expression High versus Low 1.9 (1.0–3.6) 0.049 1.62 (0.84–3.13) 0.149
Tumor differentiation < 0.001 < 0.001
Moderate versus well 2.5 (1.3–4.7) 0.005 2.2 (1.1–4.3) 0.013
Poor versus well 6.3 (2.6–15.0) < 0.001 5.4 (2.2–13.3) < 0.001
Neural invasion (NI) 0.3 (0.1–0.5) < 0.001 – –
Lymph node invasion (LNI) 0.5 (0.3–0.9) 0.038 – –
Distant metastasis 0.1 (0.0–0.3) < 0.001 – –
Tumor recurrence 0.1 (0.0–0.2) < 0.001 – –
H-score indicates histological score
Values in bold are statistically significant
The variables with P value less than 0.05 were included in multivariable analyses
hazard ratio, CI confidence interval
Table 5 Univariate and multivariate Cox regression analyses of potential prognostic factor for disease-specific survival (DSS) in
patients with colorectal cancer
Covariate Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
Nuclear TWIST1 expression High versus Low 2.04 (1.0–4.1) 0.048 1.6 (0.8–3.4) 0.158
Tumor size (cm) 1.8 (1.0–3.5) 0.040 1.5 (0.8–2.8) 0.168
Tumor differentiation < 0.001 0.003
Moderate versus well 2.7 (1.3–5.5) 0.004 2.4 (1.2–4.9) 0.013
Poor versus well 6.1 (2.4–15.7) < 0.001 5.0 (1.9–13.0) 0.001
Vascular invasion (VI) 0.4 (0.2–0.9) 0.030 – –
Neural invasion (NI) 0.3 (0.1–0.5) < 0.001 – –
Lymph node invasion (LNI) 0.5 (0.2–0.9) 0.033 – –
Distant metastasis 0.1 (0.0–0.2) < 0.001 – –
Tumor recurrence 0.1)0.05–0.20) < 0.001 – –
H-score indicates histological score
Values in bold are statistically significant
The variables with P value less than 0.05 were included in multivariable analyses
HR hazard ratio, CI confidence interval
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Moreover, CD105 is recognized as a more appropriate
marker for angiogenesis that is associated with poor
prognosis in CRC [53, 54]. In addition, our finding ex-
hibited that endothelial CD105 expression was higher in
CRC tissues compared to adjacent normal tissues, which
is in line with the results of a study by Zeljko et al. [55].
Besides, we observed and noticed of CD105 expression
in tumor cells, while very few studies have reported
cytoplasmic CD105 in tumor cells of CRC patients [27].
Data analysis also showed a statistically significant asso-
ciation between cytoplasmic of CD105 expressions of
tumor cells and TNM stage in CRC patients. Stage IV,
as the most advanced stage that occurred distant metas-
tasis, was a higher level of tumoral cytoplasmic CD105
expression in comparison with a lower stage II that
showed the association of cytoplasmic CD105 expression
in tumor cells with tumor aggressiveness in CRC. In a
recent study, cytoplasmic expression of CD105 in tumor
cells was observed in the samples of less aggressive colon
cancer [27], while CD105 expression in tumor cells was
correlated with the advanced tumor stage of kidney and
ovarian cancers [25, 56]. We have also observed a posi-
tive significant correlation between CD105 expression in
two different cells (endothelial cells and cytoplasm of
tumor cells) in CRC tissues. Accordingly, this result may
indicate that both types of cells use CD105 expression
with the same function in invasion and metastasis
events. Unlike other studies performed in this area, we
Fig. 5 Kaplan-Meier curves for disease-specific survival (DSS) and (PFS) according to the expression levels of CD105 in colorectal cancer.
(Endothelial and cytoplasmic CD105 expression in tumor cells was divided into two groups: high and low expressions’ levels). a, b Log Rank test
showed no significant differences in survival (DSS and PFS) between patients with high and low cytoplasmic CD105 expressions in tumor cells
(Survival analysis: DSS (P = 0.928) and PFS (P = 0.990)). c, d There were no significant differences in terms of survival (DSS and PFS) between
patients with high and low CD105 expressions in endothelial cells using Log Rank test (Survival analysis: DSS (P = 0.641) and PFS (P = 0.405))
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found no significant association between CD105 ex-
pression and its survival in CRC patients. In the
current study, the follow-up data was available for
138 out of 223 CRC patients in TWIST1 and 121 out
of 208 CRC patients in CD105. If we could obtain
the information about the patient’s survival outcomes
and therefore increased the number of cancer-related
deaths or events, the survival analysis might get sig-
nificant for CD105 and prognostic value of TWIST1
and CD105 expressions may be more accurately esti-
mated. In fact, by accessing all survival data, prognos-
tic value of TWIST1 and CD105 expression may be
increased.
As far as we know, the function of endothelial CD105
expression is largely known in CRC [14, 45]; however,
the role of tumoral cytoplasmic expression of CD105 is
still unclear. Studies on renal cancer introduced CD105
marker in tumor cells as a cancer stem cell marker
(CSC) [20, 57, 58] that can affect EMT [20] and contrib-
ute to chemoresistance in renal CSCs [58]. A study per-
formed on human hepatocellular carcinoma cells
(HCCs) suggested that CD105 is not only an endothelial
cell marker, but it is also expressed in liver CSCs with
mesenchymal cell features [21]. Moreover, CD105 ex-
pression was shown to be related to CSC properties in
ovarian cancer cells associated with poor prognosis and
distant metastasis [56].
Conclusions
Overexpression of TWIST1 and CD105 was detected in
CRC tissues compared to the adjacent normal tissue
samples. Our findings for the first time revealed that the
increased nuclear expression of TWIST1, rather than its
cytoplasmic expression, is associated with more ad-
vanced diseases as well as poor survival outcomes in
CRC patients in univariate analysis. In addition, we
showed that tumor differentiation was an independent
prognostic variable for PFS and DSS in CRC patients.
According to our findings, we suggest to pay more at-
tention to the role of TWIST1 expression site in cancer
cell’s function and progression, because TWIST1 plays a
critical role for the initiation of cell reprogramming in
the nucleus that is known as an important factor for
EMT induction and generation, as well as the mainten-
ance of CSCs. The present study indicated cytoplasmic
and endothelial CD105 expressions in CRC. Moreover,
our results highlight the cytoplasmic expression of
CD105 in tumor cells for the prediction of progression
and aggressive behavior in CRC. In this regard, accesses
to all the information about the patient’s survival out-
comes are required to improve our knowledge on
CD105, to clarify the prognostic impact of CD105 pro-
tein expression on patients with CRC.
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